Bristol-Myers Squibb (NYSE:BMY) Given Consensus Rating of “Hold” by Analysts

Bristol-Myers Squibb (NYSE:BMY) has been assigned a consensus recommendation of “Hold” from the twenty research firms that are currently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, three have issued a buy rating and two have assigned a strong buy rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $55.64.

A number of research analysts recently issued reports on the stock. Barclays boosted their target price on shares of Bristol-Myers Squibb from $42.00 to $43.00 and gave the company an “underweight” rating in a research report on Monday, October 7th. TD Cowen increased their price objective on shares of Bristol-Myers Squibb from $53.00 to $59.00 and gave the stock a “hold” rating in a research report on Monday, October 7th. UBS Group boosted their target price on Bristol-Myers Squibb from $50.00 to $54.00 and gave the company a “neutral” rating in a research report on Wednesday, October 9th. Bank of America reiterated a “neutral” rating and issued a $63.00 price target on shares of Bristol-Myers Squibb in a report on Tuesday, December 10th. Finally, Leerink Partners raised Bristol-Myers Squibb from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $55.00 to $73.00 in a research report on Tuesday, November 12th.

Insider Activity

In related news, SVP Phil M. Holzer sold 700 shares of the business’s stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $55.62, for a total value of $38,934.00. Following the transaction, the senior vice president now directly owns 11,760 shares of the company’s stock, valued at approximately $654,091.20. The trade was a 5.62 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Samit Hirawat acquired 1,830 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The shares were bought at an average price of $54.67 per share, with a total value of $100,046.10. Following the acquisition, the executive vice president now directly owns 62,109 shares of the company’s stock, valued at $3,395,499.03. The trade was a 3.04 % increase in their position. The disclosure for this purchase can be found here. 0.09% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Bristol-Myers Squibb

Institutional investors have recently bought and sold shares of the company. Lantz Financial LLC lifted its stake in shares of Bristol-Myers Squibb by 17.4% during the 2nd quarter. Lantz Financial LLC now owns 11,799 shares of the biopharmaceutical company’s stock valued at $490,000 after buying an additional 1,747 shares in the last quarter. Caprock Group LLC boosted its holdings in shares of Bristol-Myers Squibb by 56.0% in the second quarter. Caprock Group LLC now owns 44,767 shares of the biopharmaceutical company’s stock worth $1,859,000 after acquiring an additional 16,069 shares during the period. Quest Partners LLC grew its position in shares of Bristol-Myers Squibb by 29,957.4% in the second quarter. Quest Partners LLC now owns 40,878 shares of the biopharmaceutical company’s stock valued at $1,698,000 after purchasing an additional 40,742 shares in the last quarter. First Foundation Advisors raised its stake in shares of Bristol-Myers Squibb by 73.0% during the 2nd quarter. First Foundation Advisors now owns 5,656 shares of the biopharmaceutical company’s stock valued at $235,000 after purchasing an additional 2,386 shares during the period. Finally, Wedbush Securities Inc. lifted its holdings in Bristol-Myers Squibb by 2.4% during the 2nd quarter. Wedbush Securities Inc. now owns 60,114 shares of the biopharmaceutical company’s stock worth $2,497,000 after purchasing an additional 1,424 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Price Performance

Shares of NYSE BMY opened at $57.22 on Wednesday. The company has a quick ratio of 1.09, a current ratio of 1.24 and a debt-to-equity ratio of 2.83. The company has a market capitalization of $116.05 billion, a PE ratio of -15.94, a P/E/G ratio of 15.20 and a beta of 0.45. The firm has a fifty day simple moving average of $57.31 and a 200 day simple moving average of $51.26. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $61.08.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.49 by $0.31. The company had revenue of $11.89 billion for the quarter, compared to the consensus estimate of $11.26 billion. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. The firm’s revenue was up 8.4% compared to the same quarter last year. During the same period in the previous year, the business earned $2.00 EPS. On average, sell-side analysts forecast that Bristol-Myers Squibb will post 0.93 EPS for the current year.

Bristol-Myers Squibb Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd will be paid a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.33%. The ex-dividend date of this dividend is Friday, January 3rd. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. Bristol-Myers Squibb’s payout ratio is presently -69.08%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.